Clinical trial NCT06576271: A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants
Official title: A Phase 1, First-time-in-human, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK4527363 in Healthy Participants (Part A), Participants With Active Systemic Lupus Erythematosus (Part B), and Healthy Participants of Chinese and Japanese Descent (Part C)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Systemic Lupus Erythematosus
Keywords: Belimumab
First time in human study
GSK4527363
Healthy participants
Immunogenicity
Pharmacokinetics
Systemic lupus erythematosus
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2024-08-28
Enrollment: 138
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of GSK4527363 in healthy participants (Part A), participants with active SLE (Part B), and healthy participants of Chinese and Japanese descent (Part C).


Eligibility criteria: Inclusion Criteria:

For Part A and Part C (Healthy Participants):

* Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent form.
* Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring (vital signs and 12-lead ECG).
* Part C only: Be of Japanese (Cohort C1) or Chinese (Cohort C2) ancestry. i. Born in Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2); and ii. Descendent of 2 ethnic Japanese (Cohort C1) or Chinese (Cohort C2) parents and 4 ethnic grandparents; and iii. Have lived outside Japan (Cohort C1) or China mainland, Hong Kong or Taiwan (Cohort C2) for less than 10 years at the time of screening.
* Body weight greater than or equals to (\>=) 45 kilograms (kg).
* Body mass index (BMI) within the range 18-32 kilograms per square meter (kg/m\^2) (inclusive).
* Male or female of non-childbearing potential

For Part B (SLE participants):

* 18 to 65 years of age inclusive, at the time of signing the informed consent form
* Documented clinical diagnosis of SLE according to the (European alliance of associations of rheumatology \[EULAR\]/ American College of Rheumatology \[ACR\] SLE classification criteria)
* Body weight \>= 45 kg.
* BMI within the range 18-32 kg/m\^2 (inclusive).
* Male or female

Exclusion Criteria:

For Part A and Part C (Healthy Participants):

* History or presence or cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders.
* A history of recurrent infections, or treatment of a chronic infection within 3 months prior to the first dose of study drug.
* Any acute infection (including upper respiratory tract infections and urinary tract infections) which has not fully resolved within four weeks before dosing.
* Symptomatic herpes zoster within 3 months prior to screening.
* Have a history of malignancy, or a strong family history of malignancies related to immunosuppression.
* Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions.
* Abnormal blood pressure.
* Evidence of active or latent Tuberculosis (TB).
* Alanine transaminase (ALT) \>=1.1\* Upper limit of normal (ULN).
* Total bilirubin \>1.0\*ULN; Participants with Gilbert's syndrome can be included with total bilirubin \>=1.5\*ULN as long as direct bilirubin is \<=1.5\*ULN.
* Presence of Hepatitis B surface antigen (HBsAg) and Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.
* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
* Positive Hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention.
* Positive Human immunodeficiency virus (HIV) antibody test at screening.
* Prior medical history of anaphylaxis.
* QT interval corrected for heart rate according to Fridericia's formula (QTcF) \>450 milliseconds (msec).
* Live vaccine(s) within 30 days before the dosing day or plans to receive such vaccines during the study.

For Part B (SLE participants):

* Any acute, severe lupus related flare during the Screening Period that needs immediate treatment.
* Have clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to SLE which, in the opinion of the principal investigator (PI), could confound the results of the clinical study or put the participant at undue risk.
* Have an acute or chronic infection requiring management as follows:

  i. Currently on any suppressive therapy for a chronic infection such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster, or atypical mycobacteria.

ii. A serious infection requiring treatment with antibiotics and/or hospitalization if the last dose of antibiotics or the hospital discharge date was within 60 days of the first day of dosing (Day 1). Prophylactic anti-infective treatment is allowed.

* Evidence of active or latent TB.
* Confirmed Progressive Multifocal Leukoencephalopathy (PML) or unexplained new-onset or deteriorating neurologic signs and symptoms.
* ALT \>2\*ULN.
* Total bilirubin \>1.5\*ULN; Participants with Gilbert's syndrome can be included with total bilirubin \>1.5\*ULN as long as direct bilirubin is \>1.5\*ULN.
* Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention.
* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
* Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
* History or positive test at Screening for HIV.
* QTcF \>450 msec.
* Solid or hematological malignancy or a history of malignancy (in the past 5 years) of except for basal cell or squamous cell in situ skin carcinomas, Cervical intraepithelial neoplasia (CIN) or carcinoma in situ of the cervix that have been resected with no evidence of metastatic disease for 3 years.
* Live or live-attenuated vaccine(s) within 30 days prior to Screening

Primary outcomes:
measure: Parts A, B and C: Number of participants with non-serious adverse events and serious adverse events
timeFrame: Up to Week 52
measure: Parts A, B and C: Number of participants with clinically significant changes in physical examination, laboratory parameters, vital signs, and 12 lead electrocardiogram (ECG) findings
timeFrame: Up to Week 52
measure: Parts A, B and C: Number of participants with clinically significant changes in Columbia-Suicide Severity Rating Scale (C-SSRS)
timeFrame: Up to Week 52
Secondary outcomes:
measure: Parts A and C: Area under the concentration-time curve to the last quantifiable concentration (AUC[0-t]) of GSK4527363
timeFrame: Up to Week 52
measure: Parts A and C: Area under the concentration-time curve to infinity (AUC[0-inf]) of GSK4527363
timeFrame: Up to Week 52
measure: Parts A and C: Maximum plasma concentration (Cmax) of GSK4527363
timeFrame: Up to Week 52
measure: Parts A and C: Apparent Terminal phase half-life (t1/2) of GSK4527363
timeFrame: Up to Week 52
measure: Parts A, B and C: Number of participants with anti-drug antibodies (ADAs) against GSK4527363
timeFrame: Up to Week 52
measure: Parts A, B and C: Titers of ADAs against GSK4527363
timeFrame: Up to Week 52
measure: Parts A, B and C: Percentage change from Baseline in cytokine levels
timeFrame: Baseline (Day 1) and up to Week 52
measure: Part B: Area under the concentration-time curve to the end of the dosing period (AUC[0-tau]) of GSK4527363
timeFrame: Up to Week 52
measure: Part B: Maximum plasma concentration (Cmax) of GSK4527363
timeFrame: Up to Week 52
measure: Part B: Concentration at the end of the dosing interval (Ctrough) of GSK4527363
timeFrame: Up to Week 52
Other outcomes:
Locations:
city: Cambridge
country: United Kingdom
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: